about
Enzyme replacement and substrate reduction therapy for Gaucher diseaseAcid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipidImiglucerase in the treatment of Gaucher disease: a history and perspectiveRethinking fatigue in Gaucher diseaseProfile of eliglustat tartrate in the management of Gaucher diseaseClinical manifestations and management of Gaucher diseaseUnderstanding the natural history of Gaucher diseaseImiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapyImiglucerase and its use for the treatment of Gaucher's diseaseA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsVelaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.Individualization of long-term enzyme replacement therapy for Gaucher disease.Gaucher disease: unmet treatment needs.A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.An overview on bone manifestations in Gaucher disease.Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula.Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.Revised recommendations for the management of Gaucher disease in children.Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience.Hemorrhagic aspects of Gaucher disease.Hematological manifestations and complications of Gaucher disease.Rare Case of Hepatic Gaucheroma in a Child on Enzyme Replacement Therapy.Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trialTreatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy.Gastrointestinal disturbances and their management in miglustat-treated patients.Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG).Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature.Gaucher disease: clinical profile and therapeutic developments.Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.A reappraisal of Gaucher disease-diagnosis and disease management algorithms.A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patientsBiomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.Reducing selection bias in case-control studies from rare disease registries.Gaucher's disease: report of 11 cases with review of literature.Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1
P2860
Q24201970-CBE4E442-3578-4651-9D51-EA4BDEA3F563Q24320202-B3189646-0A0E-4028-B01D-04316D644215Q24631426-5EFCD348-97FE-47AB-8F35-A15ED4277E2AQ26748861-0B0B8D00-E736-4EBB-BCB9-40D0E6325928Q26774416-E69BD7DA-4869-4527-B6DF-9D724144EB56Q26775747-CFBF9912-752C-4AC5-A2A6-622764CA7915Q26865974-6ED78F2B-90B6-44CB-89AB-EC349AF1DBF0Q28067032-8193A1FE-866D-4DD2-BE7A-EB849EF8E7C7Q28287175-E22E5B46-5274-4976-8504-F8A6EF5FA0A2Q30235844-2847AF6F-CE87-4620-ACF3-EB9E3259E75EQ30914683-E5E647AA-62EF-4296-B9E8-180F99CEBD83Q33365037-914DC345-82B8-4E18-B535-C6BAD8232A2BQ33378952-B3DB6F35-6EE4-4B28-AFA5-A701E7DE225AQ33389419-990B0A42-45D0-41D3-9FC7-F79C8C6DD5E1Q33391428-16854A19-094B-4091-9973-9390CFBB2DE1Q33393590-4AA1EDD4-2B2D-487D-AF04-85FA97841450Q33400301-D3F7DCBC-35AC-4A66-9C32-F02690CD1A34Q33401459-E7251651-F4CF-4A95-B4CE-DDE1FEFAED9BQ33402191-0B58F5A1-77A4-457E-83D5-5A7583CD7B0DQ33411773-8E5D465A-4FA3-430C-AC2B-E1B2FC4C75B5Q33418647-ECFA6AD5-8375-404C-B3C8-E4E6995DE5F1Q33427535-1DB5A75D-43D4-4ED7-99C7-F8769BA27889Q33433356-7F40DDF5-DA4D-4C46-BBA0-C6D94E423737Q33435875-7C1BAFD1-4EB7-4F40-BBA8-0354A147FA8CQ33443605-824527BD-A986-45EF-AD2B-7BEEC0B3004FQ33451316-FE0517D4-C493-4FFF-AC55-5F0CF66B2F7AQ33588593-43499B59-B193-4836-9FD5-D37B691EBBE9Q33615625-78D3548D-93DF-4210-B4A6-AC0FCB3697F5Q33634529-5E079BF3-60EB-4649-A39B-0BB05FDE720BQ33648876-62EE4FD0-CEA9-4112-89B7-CB3C96BAA171Q34339886-5D3425ED-702A-4F0E-8B00-429494D7CEF1Q34443517-E213C43F-826A-4794-8B39-B641DF71A66EQ34485240-84A23695-D5A3-4DF1-8077-FD4133D68A53Q34683786-819D66C3-3D50-47BB-ABAD-F8CC310C05C7Q34919711-13C4265D-87FA-4AB9-B199-7173DC460FDEQ35028532-58A52E68-0030-415A-A0D5-93F7B8B13F16Q35165568-FA1E4E1F-7012-4593-94DC-95C146B7F5D3Q35439561-F74DF91C-09DF-4D5D-8391-DF8177348F7DQ35605639-5F819047-4F48-4C65-BB47-737A3DAACF5EQ35615361-13FFEFE8-A3CE-4F39-97D3-98F2BAD6DB33
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Therapeutic goals in the treatment of Gaucher disease.
@ast
Therapeutic goals in the treatment of Gaucher disease.
@en
type
label
Therapeutic goals in the treatment of Gaucher disease.
@ast
Therapeutic goals in the treatment of Gaucher disease.
@en
prefLabel
Therapeutic goals in the treatment of Gaucher disease.
@ast
Therapeutic goals in the treatment of Gaucher disease.
@en
P2093
P1476
Therapeutic goals in the treatment of Gaucher disease
@en
P2093
Generoso Andria
Gregory A Grabowski
Gregory M Pastores
Manuel Giralt
Neal J Weinreb
Pramod K Mistry
Timothy M Cox
P356
10.1053/J.SEMINHEMATOL.2004.07.009
P433
P577
2004-10-01T00:00:00Z